Trimethobenzamide hcl inj
Products billed under this code include Tigan.
Payment limit per 200 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Tigan.
Payment limit per 200 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tigan | Henry Schein Inc. | 00404-9964-02 | 1 | $62.418 |
| Tigan | Endo USA, Inc. | 42023-0119-25 | 25 | $1,560.45 |
| Tigan | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1430-01 | 1 | $62.418 |
| Tigan | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1430-03 | 25 | $1,560.45 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $62.418 | −$0.517 | 200 MG | Trimethobenzamide hcl inj | v1, posted September 17, 2026 |
| 3Q26 | $62.935 | +$5.715 | 200 MG | Trimethobenzamide hcl inj | v1, posted September 15, 2026 |
| 2Q26 | $57.22 | −$0.377 | 200 MG | Trimethobenzamide hcl inj | v1, posted September 15, 2026 |
| 1Q26 | $57.597 | +$0.091 | 200 MG | Trimethobenzamide hcl inj | v1, posted September 15, 2026 |
| 4Q25 | $57.506 | +$4.105 | 200 MG | Trimethobenzamide hcl inj | v1, posted September 8, 2026 |
| 3Q25 | $53.401 | +$3.363 | 200 MG | Trimethobenzamide hcl inj | v1, posted March 10, 2026 |
| 2Q25 | $50.038 | −$0.912 | 200 MG | Trimethobenzamide hcl inj | v1, posted March 10, 2026 |
| 1Q25 | $50.95 | −$0.279 | 200 MG | Trimethobenzamide hcl inj | v1, posted December 19, 2025 |
| 4Q24 | $51.229 | +$2.87 | 200 MG | Trimethobenzamide hcl inj | v1, posted June 11, 2025 |
| 3Q24 | $48.359 | −$0.21 | 200 MG | Trimethobenzamide hcl inj | v1, posted June 11, 2025 |
| 2Q24 | $48.569 | +$0.73 | 200 MG | Trimethobenzamide hcl inj | v1, posted March 11, 2025 |
| 1Q24 | $47.839 | +$2.894 | 200 MG | Trimethobenzamide hcl inj | v1, posted December 19, 2024 |
| 4Q23 | $44.945 | −$0.096 | 200 MG | Trimethobenzamide hcl inj | v1, posted October 10, 2024 |
| 3Q23 | $45.041 | +$0.10 | 200 MG | Trimethobenzamide hcl inj | v1, posted June 5, 2024 |
| 2Q23 | $44.941 | +$1.90 | 200 MG | Trimethobenzamide hcl inj | v1, posted February 23, 2024 |
| 1Q23 | $43.041 | +$0.16 | 200 MG | Trimethobenzamide hcl inj | v1, posted December 6, 2023 |
| 4Q22 | $42.881 | +$0.055 | 200 MG | Trimethobenzamide hcl inj | v1, posted June 22, 2023 |
| 3Q22 | $42.826 | −$0.264 | 200 MG | Trimethobenzamide hcl inj | v1, posted June 9, 2023 |
| 2Q22 | $43.09 | +$0.331 | 200 MG | Trimethobenzamide hcl inj | v1, posted December 14, 2022 |
| 1Q22 | $42.759 | +$1.856 | 200 MG | Trimethobenzamide hcl inj | v1, posted June 8, 2022 |
| 4Q21 | $40.903 | +$0.196 | 200 MG | Trimethobenzamide hcl inj | v1, posted June 2, 2022 |
| 3Q21 | $40.707 | +$0.10 | 200 MG | Trimethobenzamide hcl inj | v1, posted June 2, 2022 |
| 2Q21 | $40.607 | +$0.074 | 200 MG | Trimethobenzamide hcl inj | v1, posted March 1, 2022 |
| 1Q21 | $40.533 | – | 200 MG | Trimethobenzamide hcl inj | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.